Neuronostatin-13 trifluoroacetate salt
中文名称 | Neuronostatin-13 trifluoroacetate salt |
---|---|
中文同义词 | 生长抑素基因编码多肽NEURONOSTATIN-13 HUMAN;生长抑素基因编码多肽 |
英文名称 | Neuronostatin-13 trifluoroacetate salt |
英文同义词 | Leu-Arg-Gln-Phe-Leu-Gln-Lys-Ser-Leu-Ala-Ala-Ala-Ala-NH2 trifluoroacetate salt;L-Leucyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-lysyl-L-seryl-L-leucyl-L-alanyl-L-alanyl-L-alanyl-L-alaninamide trifluoroacetate salt;Neuronostatin trifluoroacetate salt;Neuronostatin-13 trifluoroacetate salt;Neuronostatin-13 human;L-Alaninamide, L-leucyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-lysyl-L-seryl-L-leucyl-L-alanyl-L-alanyl-L-alanyl- |
CAS号 | 1096485-24-3 |
分子式 | C64H110N20O16 |
分子量 | 1415.68 |
EINECS号 | |
相关类别 | 标准品 |
Mol文件 | 1096485-24-3.mol |
结构式 |
Neuronostatin-13 trifluoroacetate salt 性质
密度 | 1.39±0.1 g/cm3(Predicted) |
---|---|
储存条件 | -20°C |
酸度系数(pKa) | 12.90±0.46(Predicted) |
形态 | 冻干固体 |
颜色 | 白色 |
Neuronostatin-13 human is a 13-amino acid peptide hormone encoded by the somatostatin gene and plays an important role in the regulation of hormonal and cardiac function. Treatment with Neuronostatin-13 human (1,000 nM) enhances low-glucose-induced glucagon release compare with islets treated with control medium alone. Treatment with Neuronostatin-13 human for 1 h leads to a significant increase in the accumulation of glucagon mRNA compare with vehicle-treated control cells. In αTC1-9 α-cells, treatment with 100 nM Neuronostatin-13 human leads to an increase in phosphorylated PKA at 30 and 40 min.
Infusion with Neuronostatin-13 human delays glucose clearance in the rat model, such that blood glucose levels in Neuronostatin-13 human-treated animals are significantly higher at 1 and 10 min following intra-arterial injection of a glucose bolus. Chocardiographic measurement reveals a remarkable drop in heart rate after 3-, 6- and 12-hr of Neuronostatin-13 human challenge. In addition, Neuronostatin-13 human treatment significantly decreases left ventricular end-systolic diameter (LVESD) and fractional shortening without affecting left ventricular end-diastolic diameter (LVEDD) between 6 and 12 hrs following Neuronostatin-13 human challenge, the effect of which returns to basal level 18-hr after Neuronostatin-13 human treatment.
安全信息
WGK Germany | 3 |
---|
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/04/30 | HY-P1373 | Neuronostatin-13 trifluoroacetate salt Neuronostatin-13 (human) | 1096485-24-3 | 1mg | 2200元 |
2024/04/30 | HY-P1373 | Neuronostatin-13 trifluoroacetate salt Neuronostatin-13 (human) | 1096485-24-3 | 5mg | 6600元 |